|
US20040247662A1
(en)
*
|
1998-06-25 |
2004-12-09 |
Dow Steven W. |
Systemic immune activation method using nucleic acid-lipid complexes
|
|
US20030022854A1
(en)
|
1998-06-25 |
2003-01-30 |
Dow Steven W. |
Vaccines using nucleic acid-lipid complexes
|
|
US7244448B2
(en)
*
|
2000-06-30 |
2007-07-17 |
Tekmira Pharmaceuticals Corporation |
Liposomal antineoplastic drugs and uses thereof
|
|
US6723338B1
(en)
*
|
1999-04-01 |
2004-04-20 |
Inex Pharmaceuticals Corporation |
Compositions and methods for treating lymphoma
|
|
US7452550B2
(en)
*
|
2000-06-30 |
2008-11-18 |
Hana Biosciences, Inc. |
Liposomal antineoplastic drugs and uses thereof
|
|
SK7092003A3
(en)
|
2000-11-09 |
2004-06-08 |
Neopharm Inc |
SN-38 lipid complexes and methods of use
|
|
WO2003030864A1
(en)
|
2001-05-29 |
2003-04-17 |
Neopharm, Inc. |
Liposomal formulation of irinotecan
|
|
JP2005502653A
(ja)
*
|
2001-08-20 |
2005-01-27 |
トランセーヴ・インコーポレーテッド |
肺ガンの治療方法
|
|
JP2006502233A
(ja)
*
|
2002-08-02 |
2006-01-19 |
トランセーブ，インク． |
白金凝集物およびその製造方法
|
|
US9186322B2
(en)
*
|
2002-08-02 |
2015-11-17 |
Insmed Incorporated |
Platinum aggregates and process for producing the same
|
|
US20060030578A1
(en)
*
|
2002-08-20 |
2006-02-09 |
Neopharm, Inc. |
Pharmaceutically active lipid based formulation of irinotecan
|
|
EP1585504A4
(en)
*
|
2002-11-06 |
2009-07-15 |
Azaya Therapeutics Inc |
Protein stabilized liposomal formulations of pharmaceutical active ingredients
|
|
EP1643972A4
(en)
*
|
2003-06-27 |
2010-01-20 |
Smithkline Beecham Corp |
STABILIZED LIPOSOMAL TOPOTECAN COMPOSITION AND METHOD
|
|
ATE434431T1
(de)
*
|
2003-11-14 |
2009-07-15 |
Het Nl Kanker I The Netherland |
Pharmazeutische formulierungen mit kurzketten- sphingolipiden und ihre verwendung
|
|
WO2005072776A2
(en)
*
|
2004-01-30 |
2005-08-11 |
Instytut Farmaceutyczny |
Liposomal formulations of the antineoplastic agents
|
|
US20050181035A1
(en)
*
|
2004-02-17 |
2005-08-18 |
Dow Steven W. |
Systemic immune activation method using non CpG nucleic acids
|
|
US20070065522A1
(en)
*
|
2004-03-18 |
2007-03-22 |
Transave, Inc. |
Administration of high potency platinum compound formulations by inhalation
|
|
WO2005089448A2
(en)
*
|
2004-03-18 |
2005-09-29 |
Transave, Inc. |
Administration of cisplatin by inhalation
|
|
CA2928387A1
(en)
|
2004-05-03 |
2005-11-17 |
Merrimack Pharmaceuticals, Inc. |
Drug delivery liposomes containing anionic polyols or anionic sugars
|
|
US7811602B2
(en)
*
|
2004-05-17 |
2010-10-12 |
Tekmira Pharmaceuticals Corporation |
Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof
|
|
CN101001633A
(zh)
*
|
2004-05-21 |
2007-07-18 |
特兰萨夫公司 |
肺病和肺病前期病症的治疗
|
|
JP4885715B2
(ja)
*
|
2004-06-01 |
2012-02-29 |
テルモ株式会社 |
イリノテカン製剤
|
|
JP4758915B2
(ja)
*
|
2004-08-06 |
2011-08-31 |
バイオスペクトラム，インコーポレイテッド |
多重層リポソームおよびその製造方法
|
|
BRPI0516265A
(pt)
*
|
2004-10-06 |
2008-08-26 |
Bc Cancer Agency |
composição, uso da mesma, método de aumentar a retenção de um agente terapêutico dentro dos lipossomas, formulação lipossomal, e, uso de um agente terapêutico encapsulado lipossomalmente
|
|
US20090285878A1
(en)
*
|
2004-11-05 |
2009-11-19 |
Tekmira Pharmaceuticals Corporation |
Compositions and methods for stabilizing liposomal drug formulations
|
|
US20060246124A1
(en)
*
|
2004-11-08 |
2006-11-02 |
Pilkiewicz Frank G |
Methods of treating cancer with lipid-based platinum compound formulations administered intraperitoneally
|
|
CN100348194C
(zh)
*
|
2005-07-26 |
2007-11-14 |
康辰医药发展有限公司 |
盐酸洛拉曲克的脂质体制剂及其制备方法
|
|
CN100375621C
(zh)
*
|
2005-11-04 |
2008-03-19 |
唐星 |
长春瑞滨脂质微球注射液及其制备方法
|
|
WO2007056264A2
(en)
*
|
2005-11-08 |
2007-05-18 |
Transave, Inc. |
Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
|
|
US9107824B2
(en)
*
|
2005-11-08 |
2015-08-18 |
Insmed Incorporated |
Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
|
|
FR2895258B1
(fr)
|
2005-12-22 |
2008-03-21 |
Aventis Pharma Sa |
Combinaison comprenant de la combretastatine et des agents anticancereux
|
|
US20070259031A1
(en)
*
|
2006-04-26 |
2007-11-08 |
The Regents Of The University Of California |
Compositions and methods for convection enhanced delivery of high molecular weight neurotherapeutics
|
|
WO2008070009A2
(en)
*
|
2006-12-01 |
2008-06-12 |
Alza Corporation |
Treating solid tumors and monocytic leukemia using topoisomerase inhibitors in liposomes
|
|
US8067432B2
(en)
|
2008-03-31 |
2011-11-29 |
University Of Kentucky Research Foundation |
Liposomal, ring-opened camptothecins with prolonged, site-specific delivery of active drug to solid tumors
|
|
US20100093873A1
(en)
*
|
2008-10-02 |
2010-04-15 |
Goldfischer Sidney L |
Methods of improving therapy of perfluorocarbons (PFC)
|
|
US20110223675A1
(en)
*
|
2008-11-20 |
2011-09-15 |
Terumo Kabushiki Kaisha |
Drug release means from liposomes and method for evaluating releasability
|
|
US9542001B2
(en)
|
2010-01-14 |
2017-01-10 |
Brainlab Ag |
Controlling a surgical navigation system
|
|
EP2632264B1
(en)
*
|
2010-10-29 |
2019-10-02 |
Health Research, Inc. |
Novel formulations of water-insoluble chemical compounds and methods of using a formulation of compound fl118 for cancer therapy
|
|
PL226015B1
(pl)
|
2011-03-03 |
2017-06-30 |
Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną |
Liposomowy preparat zawierajacy przeciwnowotworowa substancje aktywna, sposob jego wytwarzania i zawierajaca go kompozycja farmaceutyczna
|
|
US12004868B2
(en)
*
|
2011-06-03 |
2024-06-11 |
Signpath Pharma Inc. |
Liposomal mitigation of drug-induced inhibition of the cardiac IKr channel
|
|
US10349884B2
(en)
*
|
2011-06-03 |
2019-07-16 |
Sighpath Pharma Inc. |
Liposomal mitigation of drug-induced inhibition of the cardiac ikr channel
|
|
WO2012167212A2
(en)
*
|
2011-06-03 |
2012-12-06 |
Signpath Pharma Inc. |
Liposomal mitigation of drug-induced long qt syndrome and potassium delayed-rectifier current
|
|
US10117881B2
(en)
|
2011-06-03 |
2018-11-06 |
Signpath Pharma, Inc. |
Protective effect of DMPC, DMPG, DMPC/DMPG, LYSOPG and LYSOPC against drugs that cause channelopathies
|
|
US10449193B2
(en)
*
|
2011-06-03 |
2019-10-22 |
Signpath Pharma Inc. |
Protective effect of DMPC, DMPG, DMPC/DMPG, lysoPG and lysoPC against drugs that cause channelopathies
|
|
US10238602B2
(en)
*
|
2011-06-03 |
2019-03-26 |
Signpath Pharma, Inc. |
Protective effect of DMPC, DMPG, DMPC/DMPG, LysoPG and LysoPC against drugs that cause channelopathies
|
|
US9717724B2
(en)
|
2012-06-13 |
2017-08-01 |
Ipsen Biopharm Ltd. |
Methods for treating pancreatic cancer using combination therapies
|
|
AU2013202947B2
(en)
|
2012-06-13 |
2016-06-02 |
Ipsen Biopharm Ltd. |
Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
|
|
CN121606602A
(zh)
|
2012-09-04 |
2026-03-06 |
埃莱森制药股份有限公司 |
用顺铂脂质复合物预防癌症的肺部复发
|
|
US9801874B2
(en)
|
2012-11-20 |
2017-10-31 |
Spectrum Pharmaceuticals |
Method for the preparation of liposome encapsulated vincristine for therapeutic use
|
|
JP6387400B2
(ja)
*
|
2013-05-30 |
2018-09-05 |
ナノビオティックスＮａｎｏｂｉｏｔｉｘ |
医薬組成物、その製造および使用
|
|
JP6895252B2
(ja)
|
2013-12-18 |
2021-06-30 |
サインパス ファルマ, インク.Signpath Pharma, Inc. |
心筋ｉｋｒチャネルの薬剤誘発性阻害のリポソームによる軽減
|
|
JP2017516813A
(ja)
|
2014-06-03 |
2017-06-22 |
サインパス ファルマ, インク.Signpath Pharma, Inc. |
チャネル病を引き起こす薬物に対するｄｍｐｃ、ｄｍｐｇ、ｄｍｐｃ／ｄｍｐｇ、ｅｇｐｇ、ｌｙｓｏｐｇ及びｌｙｓｏｐｃの防御効果
|
|
ES2951598T3
(es)
*
|
2014-11-25 |
2023-10-23 |
Curadigm Sas |
Composición farmacéutica que combina al menos dos nanopartículas distintas y un compuesto farmacéutico, preparación y usos de los mismos
|
|
US11318131B2
(en)
*
|
2015-05-18 |
2022-05-03 |
Ipsen Biopharm Ltd. |
Nanoliposomal irinotecan for use in treating small cell lung cancer
|
|
TWI678213B
(zh)
|
2015-07-22 |
2019-12-01 |
美商史倍壯製藥公司 |
用於長春新鹼硫酸鹽脂質體注射之即可使用的調配物
|
|
EP3337467B1
(en)
|
2015-08-20 |
2020-12-09 |
Ipsen Biopharm Ltd. |
Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
|
|
MX385425B
(es)
|
2015-08-21 |
2025-03-18 |
Ipsen Biopharm Ltd |
Irinotecán liposomal y oxaliplatino, 5-fluoroacilo y leucovorina para usarse en el tratamiento de cáncer pancreático metastásico.
|
|
CA2940470C
(en)
*
|
2015-09-18 |
2019-08-20 |
Signpath Pharma Inc. |
Treatment for glioblastoma
|
|
MX382522B
(es)
|
2015-10-16 |
2025-03-13 |
Ipsen Biopharm Ltd |
Composiciones farmaceuticas estabilizantes de camptotecina.
|
|
WO2017106630A1
(en)
|
2015-12-18 |
2017-06-22 |
The General Hospital Corporation |
Polyacetal polymers, conjugates, particles and uses thereof
|
|
KR102638618B1
(ko)
|
2016-04-27 |
2024-02-21 |
사인패스 파마 인코포레이티드 |
약물 유발된 방실 차단의 방지
|
|
WO2018031968A1
(en)
|
2016-08-12 |
2018-02-15 |
L.E.A.F. Holdings Group Llc |
Alpha and gamma-d polyglutamated antifolates and uses thereof
|
|
KR102350647B1
(ko)
|
2016-09-02 |
2022-01-14 |
다이서나 파마수이티컬, 인크. |
4'-포스페이트 유사체 및 이를 포함하는 올리고뉴클레오타이드
|
|
EP3535026A1
(en)
|
2016-11-02 |
2019-09-11 |
Ipsen Biopharm Limited |
Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin)
|
|
FI3603620T3
(fi)
|
2017-03-31 |
2025-12-02 |
Fujifilm Corp |
Liposomikoostumus ja farmaseuttinen koostumus
|
|
US12239734B2
(en)
|
2018-02-07 |
2025-03-04 |
L.E.A.F. Holdings Group Llc |
Gamma polyglutamated raltitrexed and uses thereof
|
|
WO2019157129A1
(en)
|
2018-02-07 |
2019-08-15 |
L.E.A.F. Holdings Group Llc |
Alpha polyglutamated pralatrexate and uses thereof
|
|
US12220431B2
(en)
|
2018-02-07 |
2025-02-11 |
L.E.A.F. Holdings Group Llc |
Gamma polyglutamated antifolates and uses thereof
|
|
EP3749311A4
(en)
|
2018-02-07 |
2022-07-06 |
L.E.A.F Holdings Group LLC |
PEMETREXED POLYGLUTAMATE GAMMA COMPOSITIONS AND THEIR USES
|
|
CN111954531A
(zh)
|
2018-02-07 |
2020-11-17 |
L.E.A.F.控股集团公司 |
α聚谷氨酸化培美曲塞及其用途
|
|
WO2019157123A1
(en)
|
2018-02-07 |
2019-08-15 |
L.E.A.F. Holdings Group Llc |
Alpha polyglutamated aminopterin and uses thereof
|
|
WO2019160732A1
(en)
*
|
2018-02-14 |
2019-08-22 |
L.E.A.F. Holdings Group Llc |
Gamma polyglutamated aminopterin and uses thereof
|
|
CN111936145A
(zh)
|
2018-02-14 |
2020-11-13 |
L.E.A.F.控股集团公司 |
γ聚谷氨酸化氨甲蝶呤及其用途
|
|
TWI737974B
(zh)
*
|
2018-04-09 |
2021-09-01 |
美商標徑製藥公司 |
用於治療增生性失調的劑量方案
|
|
CN112437674A
(zh)
*
|
2018-04-11 |
2021-03-02 |
新墨西哥科技大学研究园公司 |
用于药物递送的脂质前药
|
|
PL3811931T3
(pl)
|
2018-06-20 |
2024-11-18 |
Fujifilm Corporation |
Skojarzony środek leczniczy zawierający kompozycję liposomową z kapsułkowanym lekiem i inhibitor punktu kontroli immunologicznej
|
|
WO2020071349A1
(ja)
|
2018-10-01 |
2020-04-09 |
富士フイルム株式会社 |
薬物を内包するリポソーム組成物およびプラチナ製剤を含む組合せ医薬
|
|
WO2020205473A1
(en)
|
2019-03-29 |
2020-10-08 |
Decerna Pharmaceuticals, Inc. |
Compositions and methods for the treatment of kras associated diseases or disorders
|
|
WO2020226960A1
(en)
|
2019-05-03 |
2020-11-12 |
Dicerna Pharmaceuticals, Inc. |
Double-stranded nucleic acid inhibitor molecules with shortened sense strands
|
|
US12053551B2
(en)
*
|
2019-12-20 |
2024-08-06 |
Translate Bio, Inc. |
Process of preparing mRNA-loaded lipid nanoparticles
|
|
BR112022013821A2
(pt)
|
2020-01-15 |
2022-09-13 |
Dicerna Pharmaceuticals Inc |
Ácidos nucleicos de 4?-o-metileno fosfonato e seus análogos
|
|
IL300283A
(en)
|
2020-08-04 |
2023-04-01 |
Dicerna Pharmaceuticals Inc |
Systemic administration of oligonucleotides
|
|
JPWO2022250015A1
(https=)
|
2021-05-24 |
2022-12-01 |
|
|
|
TW202313031A
(zh)
|
2021-05-24 |
2023-04-01 |
日商富士軟片股份有限公司 |
抗腫瘤劑
|